Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by jay_dog992003on Mar 15, 2014 1:22pm
134 Views
Post# 22327567

RE:RE:RE:RE:RE:RE:Level II

RE:RE:RE:RE:RE:RE:Level IIAlso, you said "do not all ways think loi is going to make a stock go up" (it is spelt always*) but the basis of investors thinking the stock was going to rise was based on the fact that the company had converted three letters of intent into actual contracts.  The Wanbang contract also gave Sirona its first revenue.  

That being said, management has messed up along the way.  They were unlucky to have both deals signed while a private placement was outstanding.  Obviously it was even worse that they couldn't fill the placement at their desired price.  However, they secured some funds for day-to-day activities and it appears that funding from the French government should be here shortly, which won't be dilutive.
Bullboard Posts